Guselkumab for moderately to severely active ulcerative colitis

被引：0
|
作者：
不详
机构：
来源：
LANCET GASTROENTEROLOGY & HEPATOLOGY | 2025年 / 10卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：112 / 112
页数：1
相关论文
共 50 条
  • [1] Guselkumab: A New Therapeutic Option for the Treatment of Moderately to Severely Active Ulcerative Colitis
    Bhat, Shubha
    Choi, David
    ANNALS OF PHARMACOTHERAPY, 2025,
  • [2] Golimumab for moderately to severely active ulcerative colitis
    Kedia, Saurabh
    Ahuja, Vineet
    Makharia, Govind K.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (10) : 1273 - 1282
  • [3] Filgotinib for moderately to severely active ulcerative colitis
    Mannucci, Alessandro
    D'Amico, Ferdinando
    El Saadi, Ahmad
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 16 (10) : 927 - 940
  • [4] QUASAR Induction Study 1 Cumulative Response to Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis
    Peyrin-Biroulet, L.
    Rubin, D.
    Lichtenstein, G.
    Shipitofsky, N.
    Huang, K. H.
    Germinaro, M.
    Wilson, R.
    Zhang, H.
    DuVall, G. A.
    Cao, Q.
    Allegretti, J.
    Feagan, B.
    Hisamatsu, T.
    Panes, J.
    Dignass, A.
    Bressler, B.
    Sands, B.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 624 - 625
  • [5] QUASAR Induction Study 1 Cumulative Response to Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis
    Sands, Bruce E.
    Rubin, David T.
    Lichtenstein, Gary
    Shipitofsky, Nicole
    Huang, Kuan-Hsiang
    Germinaro, Matthew
    Wilson, Rebbecca
    Zhang, Hongyan
    DuVall, Aaron
    Cao, Qian
    Allegretti, Jessica R.
    Feagan, Brian G.
    Peyrin-Biroulet, Laurent
    Hisamatsu, Tadakazu
    Panes, Julian
    Dignass, Axel
    Bressler, Brian
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S526 - S527
  • [6] Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis
    Dulai, Parambir S.
    Mosli, Mahmoud
    Khanna, Reena
    Levesque, Barrett G.
    Sandborn, William J.
    Feagan, Brian G.
    PHARMACOTHERAPY, 2015, 35 (04): : 412 - 423
  • [7] Guselkumab induction restores intestinal immune homeostasis and promotes epithelial repair in moderately to severely active Ulcerative Colitis
    Sridhar, S.
    Hart, A.
    Venkat, S.
    Ruane, D.
    Horowitz, D.
    Lee, T.
    Waterworth, D.
    Huang, K. H. G.
    Germinaro, M.
    Vetter, M.
    Cua, D.
    Freeman, T. C.
    Sisk, C.
    McRae, B.
    Verstockt, B.
    Rubin, D. T.
    Sands, B. E.
    Branigan, P.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I41 - I41
  • [8] Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study
    Peyrin-Biroulet, Laurent
    Allegretti, Jessica R.
    Rubin, David T.
    Bressler, Brian
    Germinaro, Matthew
    Huang, Kuan-Hsiang
    Shipitofsky, Nicole
    Zhang, Hongyan
    Wilson, Rebbecca
    Han, Chenglong
    Feagan, Brian G.
    Sandborn, William J.
    Panes, Julian
    Hisamatsu, Tadakazu
    Lichtenstein, Gary R.
    Sands, Bruce E.
    Dignass, Axel
    GASTROENTEROLOGY, 2023, 165 (06) : 1443 - 1457
  • [9] GUSELKUMAB INDUCTION RESTORES INTESTINAL IMMUNE HOMEOSTASIS AND PROMOTES EPITHELIAL REPAIR IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Sridhar, Sunan
    Hart, Amy
    Venkat, Swati
    Ruane, Darren
    Horowitz, Dan
    Lee, Tae
    Waterworth, Dawn M.
    Huang, Kuan-Hsiang G.
    Germinaro, Matthew
    Vetter, Marion
    Cua, Daniel
    Freeman, Tom C.
    Sisk, Christopher
    Mcrae, Bradford
    Verstockt, Bram
    Rubin, David T.
    Sands, Bruce E.
    Branigan, Patrick
    GASTROENTEROLOGY, 2024, 166 (05) : S790 - S790
  • [10] Combination Therapy With Guselkumab and Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Pharmacokinetics, Immunogenicity and Drug-Drug Interactions
    Shao, Jie
    Vetter, Marion
    Vermeulen, An
    Feagan, Brian G.
    Sands, Bruce E.
    Panes, Julian
    Xu, Zhenhua
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 (06) : 1418 - 1427
12345